There have been a few items in the news lately related to Inflammatory Bowel Disease that I thought prudent to pass along to everyone.
Tysabri Update:
A few weeks ago I wrote about the multiple sclerosis drug, Like what you're reading? Get email notifications when Elizabeth Roberts posts, or get updates on Facebook, iGoogle, your personal blog and more!
< Previous Post:
The Food DebateNext Post: >
My Elimination Diet-
Re: Tysabri and potential liver problems
Barbara J Childs
Thursday, March 06, 2008 at 07:36 AMre: Re: Tysabri and potential liver problems
Elizabeth Roberts
Thursday, March 06, 2008 at 04:44 PMYou're correct that the letter came from Biogen and Elan, however, it was the FDA who required them to send it.
My purpose here is not to dicker over who/what, but simply to make potential Tysabri user's aware of all potential side effects when making the decision whether or not to use this drug.
Thanks for your input.
replyre: re: Re: Tysabri and potential liver problems
Nicholas Bumblefuss
Friday, April 04, 2008 at 12:55 PMIt is pertinent here to name the fact that Barbara Childs is an Elan Pharmaceuticals stockholder. She launched an internet attack against a single blog post referencing Elan on April 2nd, 2008 because it was not to her liking, and then engaged in a series of false and misleading forum posts on a website for Elan investors in order to incite a mob response. I am not surpised to see her prior attempt here to rewrite your fine article.
reply
People who read this also read...
What the community is saying...
"If You Have Crohn's Disease, Don't Smoke"
Posted 09/17 Comments (0)
The title of this SharePost is a direct quote from...
The Dear Doc letter was sent by Biogen Idec and Elan NOT the FDA. It was not because of new cases with liver damage (see following statement by Sandy Walsh of FDA). It was sent to bring doctors who treat MS patients current with the labelling for those who treat Crohn's. BTW, a few years ago Biogen Idec sent the same letter out to doctors warning them of liver damage from Avonex. All MS drugs have had liver toxicity problems and is NOT unique to Tysabri. In fact, the incidence for Tysabri is less than some of the other drugs.
FDA spokeswoman Sandy Walsh, however, said the letter does not reflect new cases but is simply a reiteration of a revised label the FDA approved Jan. 16 as part of the expanded use of the drug for the bowel disorder Crohn's disease. (Reporting by Kim Dixon, editing by Gerald E. McCormick)
reply